Evidence map›Paper›PMID 40950202›Full record

ArticlebioRxiv : the preprint server for biology2025

Poly(ADP-ribose) Polymerase 1 Deficiency Attenuates Amyloid Pathology, Neurodegeneration, and Cognitive Decline in a Familial Alzheimer's Disease Model.

Aanishaa Jhaldiyal, Manisha Kumari, Trupti Tripathi, Mohammed Repon Khan, Justin Wang, Lauren Guttman, Devanik Biswas, Abhishek Pasupuleti, Akansha Aggarwal, Shraddha Pandya and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Aanishaa JhaldiyalNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.ORCID 0000-0002-0620-7390
Manisha KumariNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Trupti TripathiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Mohammed Repon KhanNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Justin WangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Lauren GuttmanNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Devanik BiswasNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Abhishek PasupuletiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Akansha AggarwalNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Shraddha PandyaNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Shih-Ching ChouNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Nikhil PanickerNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Abhay MonghekarDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Marilyn AlbertDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Lynn M BekrisDepartment of Laboratory Medicine and Pathology, University of Washington, Harborview Research and Training Building, 300 Ninth Ave, Box 359665, Seattle, WA 98104.
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology, Cleveland Clinic, Cleveland, OH 44195, USA.
Tae-In KamNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.ORCID 0000-0002-6459-0893
Valina L DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.ORCID 0000-0002-2915-3970

Funding

Project 2 MeasurementU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2014 to 2026
$51.5M
Poly (ADP-Ribose) and AIF in Neuronal InjuryR01NS067525 · NINDS · JOHNS HOPKINS UNIVERSITY · PI VALINA L. DAWSON, Ted M. Dawson · 2010 to 2026
$6.0M
Parthanatos, AIF and PAAN-1 in Neuronal InjuryR37NS067525 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M., DAWSON, VALINA L. · 2015 to 2021
$5.3M
MIF Nuclease actions in Synuclein DementiasR01AG085688 · NIA · JOHNS HOPKINS UNIVERSITY · PI VALINA L. DAWSON, Ted M. Dawson · 2024 to 2026
$2.4M
ASC oligomerization and transmission as an initiating event for protein aggregation in Synucleinopathy DementiasR00AG066862 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI PANICKER, NIKHIL · 2022 to 2024
$747k
NIA NIH HHS R00 AG066862NIA NIH HHS R01 AG085688NIA NIH HHS U19 AG033655NINDS NIH HHS R01 NS067525NINDS NIH HHS R37 NS067525
6 · The paper itself

Abstract

Poly(ADP-ribose) (PAR) polymerase-1 (PARP1) has been implicated in DNA damage responses and neuroinflammation in Alzheimer's disease (AD), yet its role in amyloid-β (Aβ) pathology remains unclear. Here, we show that PARP1 activation drives Aβ pathology and neurodegeneration. Using a sensitive ELISA, we observed significantly elevated PAR levels in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD compared to controls.

Indexed as

Alzheimer’s diseaseAmyloid beta (Aβ)NeurodegenerationPARP1Poly(ADP-ribose) (PAR)

Identifiers

PMID40950202
PMCPMC12424659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.